Stroke Drug Development Targeting Other Components

There are many other factors that influence the course of a stroke episode. Ace Therapeutics offers comprehensive services to develop stroke drug studies that target different factors in the stroke process. We have established a comprehensive service to explore the pathogenesis of stroke, which allows for comprehensive screenings of pathways with potential for drug development. We also provide comprehensive drug development services for different mechanisms of action to ensure the integrity and scientific validity of stroke drug development studies.

Stroke Drug Development Targeting Excitotoxicity

Stroke Drug Development Targeting Excitotoxicity

Excitotoxicity is an important pathological process during a stroke attack. It is an effective stroke therapy to alleviate the excitotoxic response during a stroke attack. In view of this, Ace Therapeutics offers comprehensive services for the development of stroke therapies targeting excitotoxicity. Our services focus on targeting glutamate and NMDAR and its subunits and exploring the role of glutamate- and NMDAR-related signaling pathways in stroke pathology in a comprehensive approach to stroke drug development.

Stroke Drug Development Targeting Different Physiological Processes

Stroke Drug Development Targeting Different Physiological Processes

A number of physiological and pathological processes are critical for the regulation of the stroke pathological process. Therefore, it is an important pathway to target these physiological and pathological processes to develop new stroke drugs. In view of this, Ace Therapeutics offers comprehensive services for the development of new stroke drugs. We provide comprehensive targeted drug development services for physiological processes involved in stroke attacks, such as autophagic processes and epigenetic mechanisms.

Stroke Drug Development Targeting Others

Stroke Drug Development Targeting Others

Several organelles, tissues, and others are essential for the regulation of stroke pathological processes. Therefore, it is an important pathway to target organelles and tissues for stroke drug development. With this in mind, Ace Therapeutics provides high-quality services to target organelles, tissues, and other in vivo structures for the development of new stroke drugs. We offer comprehensive targeted drug development services for different structures involved in stroke pathologies such as mitochondria, blood brain barrier, and other structures.

Why Choose Us

Ace Therapeutics is a preclinical CRO biotechnology company focused on the stroke field. We have decades of research experience in the stroke field.

  • Professional Scientists

Our scientists have decades of research experience in the field of stroke, and we are constantly learning and advancing to ensure an up-to-date knowledge base and skill set.

  • Advanced Technologies

We have decades of research experience in the field of stroke, and we are constantly learning to enhance our expertise.

  • Full Equipment

Our full range of equipment ensures comprehensive coverage of research services.

Our services are flexible and can be tailored to your research and needs. If you would like to learn more about our services, please feel free to contact us.

All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
0
Inquiry Basket